文献速递糖尿病

2型糖尿病患者药物依从性的尿液生化检测及其与临床标志物的关联:DIALECT队列分析

Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT).
PubMed 文献 · Diabetes Care · 2021-04-23

该研究基于DIALECT队列457例2型糖尿病患者的基线数据,采用液相色谱-串联质谱检测尿液,评估口服降糖药、降压药和他汀类药物的依从性。总体依从率为89.3%,非依从患者微血管和大血管并发症患病率显著更高,LDL胆固醇达标率更低。

要点

  • 尿液生化检测可客观评估2型糖尿病患者的药物依从性。
  • 非依从患者微血管和大血管并发症患病率显著更高。
  • 非依从患者LDL胆固醇≤2.5 mmol/L达标率更低。

核心结论

  • 尽管专科管理的真实世界2型糖尿病患者药物依从性相对较高,但非依从患者微血管和大血管并发症患病率显著更高,治疗目标达标率更低。
  • 强调客观检测和个体化干预以提高依从性的重要性。

研究设计与样本

  • DIALECT队列基线数据分析,纳入457例2型糖尿病患者。
  • 采用液相色谱-串联质谱分析基线尿样,评估口服降糖药、降压药和他汀类药物的依从性。
  • 主要结局为微血管和大血管并发症以及LDL胆固醇、HbA1c和血压的治疗目标,横断面评估。

主要发现

  • 总体89.3%的患者被判定为依从。
  • 口服降糖药、降压药和他汀类的依从率分别为95.7%、92.0%和95.5%。
  • 非依从患者微血管并发症患病率81.6% vs. 66.2%(P=0.029),大血管并发症55.1% vs. 37.0%(P=0.014)。
  • 非依从患者LDL胆固醇≤2.5 mmol/L达标率67.4% vs. 81.1%(P=0.029)。
  • 二元逻辑回归显示较高BMI、当前吸烟、血清LDL胆固醇升高、HbA1c升高、糖尿病肾病和大血管疾病与不依从相关。

关键数值与推荐

  • 微血管并发症患病率:非依从81.6% vs. 依从66.2%,P=0.029。
  • 大血管并发症患病率:非依从55.1% vs. 依从37.0%,P=0.014。
  • LDL胆固醇≤2.5 mmol/L达标率:非依从67.4% vs. 依从81.1%,P=0.029。

临床怎么用

  • 可考虑使用尿液生化检测客观识别药物不依从的2型糖尿病患者。
  • 对非依从患者应加强关注微血管和大血管并发症及治疗目标达标情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess adherence to the three main drug classes in real-world patients with type 2 diabetes using biochemical urine testing, and to determine the association of nonadherence with baseline demographics, treatment targets, and complications. RESEARCH DESIGN AND METHODS: Analyses were performed of baseline data on 457 patients in the DIAbetes and LifEstyle Cohort Twente (DIALECT) study. Adherence to oral antidiabetics (OADs), antihypertensives, and statins was determined by analyzing baseline urine samples using liquid chromatography-tandem mass spectrometry. Primary outcomes were microvascular and macrovascular complications and treatment targets of LDL cholesterol, HbA1c, and blood pressure. These were assessed cross-sectionally at baseline. RESULTS: Overall, 89.3% of patients were identified as adherent. Adherence rates to OADs, antihypertensives, and statins were 95.7%, 92.0%, and 95.5%, respectively. The prevalence of microvascular (81.6% vs. 66.2%; P = 0.029) and macrovascular complications (55.1% vs. 37.0%; P = 0.014) was significantly higher in nonadherent patients. The percentage of patients who reached an LDL cholesterol target of ≤2.5 mmol/L was lower (67.4% vs. 81.1%; P = 0.029) in nonadherent patients. Binary logistic regression indicated that higher BMI, current smoking, elevated serum LDL cholesterol, high HbA1c, presence of diabetic kidney disease, and presence of macrovascular disease were associated with nonadherence. CONCLUSIONS: Although medication adherence of real-world type 2 diabetes patients managed in specialist care was relatively high, the prevalence of microvascular and macrovascular complications was significantly higher in nonadherent patients, and treatment targets were reached less frequently. This emphasizes the importance of objective detection and tailored interventions to improve adherence.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Beernink JM, Oosterwijk MM, Khunti K, et al. Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT). Diabetes Care. 2021. PMID: 33893164. doi:10.2337/dc20-2533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。